NADMED Partners with Altheome to Bring Advanced NAD Testing to UK Clinics and Consumers

NADMED, the developer of the most accurate and only CE-marked test for measuring NAD levels, has announced a partnership with Altheome, a specialist biomarker and diagnostics technology company, to expand access to advanced NAD testing for clinics, pharmaceutical companies and consumers in the UK.   Through this collaboration, Altheome will integrate NADMED’s breakthrough NAD testing technology into its biomarker and diagnostics services, enabling UK clinics to offer accurate NAD measurement via a venous blood draw as part of their health, wellness, and precision medicine programmes. The partnership also lays the foundation for broader consumer access to high-quality, biomarker-driven health insights.   NADs (Nicotinamide Adenine Dinucleotides) are the body’s natural forms of vitamin B3 and play a critical role in energy metabolism, DNA repair, and overall cellular health. Low or imbalanced NAD levels have been associated with metabolic disorders, neurodegenerative diseases, and impaired cellular resilience. NADMED method, developed at the University of Helsinki, allows measuring both forms of NAD: NAD+ and NADH. Besides the levels, their ratio provides valuable insight into mitochondrial function, biological ageing, and metabolic health.   Until recently, NAD testing has been costly, slow, and often unreliable. NADMED, a spin-out from the University of Helsinki, has developed an innovative lab-based solution that delivers fast, accurate, and cost-effective measurement of NAD+ and NADH, making scalable and clinically relevant NAD analysis possible.   Altheome is a specialist biomarker and diagnostics technology company advancing precision medicine by delivering ultra-accurate, high-quality biomarker measurement, analytical services, and diagnostics to life sciences and clinical partners. Its mission is to transform research concepts into impactful insights that accelerate discovery, validation, and clinical translation of biomarkers across therapeutic areas.   Acting as a strategic partner to researchers, physicians, clinics, academia, biotechnology, and biopharmaceutical organisations, Altheome turns complex biological questions into meaningful data and actionable outcomes. The company was founded out of a desire to raise scientific standards in the sector, combining best-in-class technologies, rapid turnaround, and a deeply science-driven team.   By incorporating NADMED’s technology, Altheome will support clinics with the logistics, analysis, and interpretation required to make NAD testing accessible and actionable, helping translate complex metabolic data into meaningful health insights.   Jari Närhi, CEO of NADMED, commented, “We are excited to work with Altheome to expand access to our CE-marked NAD test in the UK. Their strength in biomarker science and diagnostics, combined with a collaborative and quality-driven approach, makes them an ideal partner to help bring accurate NAD measurement into clinical and consumer health settings.”   Adam Shellard, Founder and CEO of Altheome, commented, “At Altheome, our focus is on delivering the highest-quality biomarker data and turning it into insights that matter. Partnering with NADMED allows us to offer clinics and, soon, consumers access to one of the most important metabolic biomarkers through a robust, clinically validated technology. This is an important step in making biomarker-driven health monitoring more precise, accessible, and actionable.”